Skip to main content

Deal Alert: ChrysCapital invests Rs.300-Cr in Intas Pharma

From the Press Release:

Ahmedabad-based Intas Pharma, one of India’s leading private pharmaceutical companies, today announced that it is raising Rs. 300 crores from ChrysCapital in a pre-IPO round.  The Company has deferred its listing plans for the time being and intends to re-file for an IPO once market conditions stabilize.

Intas is an established global pharmaceutical player with FY 2012 revenues of over Rs. 2,700 crores.  The Company has a strong presence in chronic therapy areas and is currently ranked 12th in the domestic market by ORG-IMS.  Intas also has a fast growing and significant export base in Europe and USA under the brand name of Accord Healthcare.

This will be ChrysCapital’s second investment in Intas, having originally backed the Company in 2006 from an older fund.  As an existing investor in the Company, ChrysCapital has benefited significantly from the strong performance recorded by Intas over the past six years.  Consequently, this investment comes at a significant multiple to the 2006 investment.

Based on the Chairman, Hasmukh Chudgar’s recommendation, the Board of Directors endorsed the appointments of Binish Chudgar as the Vice-Chairman & MD and Nimish Chudgar as the MD & CEO with immediate effect. These appointments are to drive forward the Company’s ambitious growth plans and develop world-class leadership in the run-up to a public listing in the near future.

Binish Chudgar of Intas commented, “ChrysCapital has been an integral part of our journey and has played an important role in determining our business strategy along the way.  We greatly value ChrysCapital as an investment partner and look forward to extending our association further.”

Sanjiv Kaul, ChrysCapital’s nominee on the board of the Company, said, “Intas has demonstrated impressive historical growth and profitability and is poised for significant growth in the years ahead.  The Company has gained market share in a fast growing domestic market and successfully scaled up its international business at the same time.  This follow-on investment reaffirms ChrysCapital’s faith in the Company’s ability to continue to deliver superior shareholder value over the years.”

About Intas Pharmaceuticals Limited
Intas is a leading, vertically integrated Indian pharmaceutical company engaged in the development, manufacture and marketing of formulations including bio-pharmaceuticals. In the domestic market, the Company has over 55% of its revenues coming from chronic therapy areas like cardio and central nervous system.  Internationally, Intas is present in over 50 countries worldwide predominantly in North America, Europe & Latin America with exports constituting around 40% of total revenues. The Company operates 10 manufacturing facilities with approvals from leading regulatory agencies like the USFDA.

About ChrysCapital
ChrysCapital manages $2.5 billion across six funds and is one of the leading private equity funds that invest in India. With 60 investments since 1999, ChrysCapital has valuable experience in evaluating investment opportunities across a breadth of sectors that leverage growth in the Indian economy.

For further information, please contact:
Binish Chudgar, Vice-Chairman & Managing Director, Intas Pharma
Tel: 079 – 2657 6655
E-mail: binish_chudgar@intaspharma.com

Jayesh Shah, CFO, Intas Pharma
Tel: 91-9998050507
E-mail: jayesh@intaspharma.com

Popular posts from this blog

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE

PE-VC investments fall 38% in 2023 to below $30 B

The value of investments by Private Equity - Venture Capital (PE-VC) firms in India fell by 38% to less than $30 Billion in 2023. PE-VC firms invested $29.7 Billion (across 756 deals) in Indian companies in 2023, compared to $47.6 Billion (across 1,362 deals) in the previous year, reports Venture Intelligenc e, a research service focused on private company financials, transactions, and their valuations. (Note: These figures exclude PE investments in Real Estate).                                                                                                                                                                      2023 witnessed 67 mega deals ($100 M+ rounds) worth $21.2 Billion, compared to 112 such investments worth $31.8 Billion in 2022. The $2.4 Billion investment in Manipal Hospitals by Temasek (which gained majority control) and TPG Capital was the largest PE-VC investment in 2023. This was followed by the $1.35 Billion buyout of education loans focused HDFC Credila